News — Airna

For interview requests or other media engagements, email our communications team at info@airna.com.

Press Releases

2 June 2026

AIRNA Appoints Industry Veteran Todd Bazemore as President and CEO to Drive the Next Stage of Company Growth

– Mr. Bazemore joins AIRNA with over 30 years of experience leading clinical- and commercial-stage biotechs with a focus on rare diseases CAMBRIDGE, Mass., June 2, 2026 – AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, today announced that Todd Bazemore has been appointed President and […]

Read

12 May 2026

AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT

– AIR-001 demonstrated best-in-class potential, achieving up to 59% precise RNA editing in vivo and restoring 40 µM functional M-AAT in a mouse model of AATD – Preclinical data show RNA editing can introduce protective variants for cardiovascular disease and drive reduction of LDL cholesterol levels CAMBRIDGE, Mass., May 12, 2026 – AIRNA, a biotech […]

Read

In the News

Yahoo!Finance

1 April 2026

RNA editing: emerging from CRISPR’s shadow

View

In the News

Endpoints

1 April 2026

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

View

In the News

Fierce Biotech

1 April 2026

AIRNA nets $155M series B to launch clinical test of RNA editing tech

View

In the News

GEN Edge

31 July 2024

RNA Editing Therapy Developer Closes $60M Series A Financing

View

In the News

BioPharma Dive

31 July 2024

Biotech Airna raises $60M for RNA editing medicines

View

Publications

ASGCT Annual Meeting

12 May 2026

AIR-001: A highly potent and precise GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency

View

Publications

ASGCT Annual Meeting

12 May 2026

RNA Editing: A Modality for Precise Introduction of Gain-of-Function Variants Identified by Human Genetics

View

Publications

OTS Annual Meeting

21 October 2025

Building a Leading RNA Editing Platform for the Treatment of Genetic Diseases

View

Publications

ASGCT Annual Meeting

14 May 2025

Optimized RESTORE+ oligonucleotides for an efficacious and safe RNA base editing treatment for Alpha-1 Antitrypsin Deficiency

View

Publications

Nature Biotechnology

21 September 2023

Precision RNA base editing with engineered and endogenous effectors

Laura S Pfeiffer, Thorsten Stafforst. doi: 10.1038/s41587-023-01927-0.

View

Publications

Nature Biotechnology

28 January 2019

Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides

Merkle T, Merz S, Reautschnig P, Blaha A, Li Q, Vogel P, Wettengel J, Li JB, Stafforst T. Nat Biotechnol 2019, 37:133-138, doi: 10.1038/s41587-019-0013-6, PMID: 30692694.

View

Publications

Nucleic Acids Research

29 August 2017